Longitudinal Investigation of I2BS in PD
NCT05516719 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 44
Last updated 2025-10-07
Summary
In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function
Conditions
- Parkinson's
- Parkinson Disease
- Parkinson's Disease
- Neurodegenerative Diseases
- Neurodegeneration
- Positron Emission Tomography
Interventions
- OTHER
-
Positron Emission Tomography (PET) scan using BU99008 tracer
A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
- OTHER
-
FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
- OTHER
-
Magnetic Resonance Imaging (MRI) Scan
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
- OTHER
-
Lumbar puncture
A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic. This allows the collection of Cerebrospinal fluid ( CSF)
Sponsors & Collaborators
-
University of Exeter
lead OTHER
Principal Investigators
-
Marios Politis, Professor · University of Exeter
Eligibility
- Min Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-11-01
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Identifying New Biomarkers of Parkinson's From Routine Brain Imaging
NCT04986020 ·Status: UNKNOWN
-
Neuromelanin MRI: A Progression Marker in Early PD
NCT05631158 ·Status: UNKNOWN
-
Novel Neuroimage Study in Tauopathies With Parkinsonism
NCT03386669 ·Status: COMPLETED ·Phase: PHASE2
-
Precision Medical Diagnosis for Parkinson's Disease - The Quantitative Analysis System for PET/MRI Images in Patients
NCT03909828 ·Status: UNKNOWN
-
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
NCT06289582 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Translocator Protein PET/CT in Various TSPO-Related Disease
NCT06725719 ·Status: RECRUITING
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT02103894 ·Status: COMPLETED ·Phase: PHASE1
-
Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease
NCT02605161 ·Status: COMPLETED
-
Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan
NCT02855021 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
NCT01462708 ·Status: COMPLETED ·Phase: PHASE1
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
NCT00613119 ·Status: COMPLETED
-
Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes
NCT04557865 ·Status: COMPLETED ·Phase: NA
-
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
NCT00427674 ·Status: TERMINATED ·Phase: PHASE1
-
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
NCT01696708 ·Status: COMPLETED ·Phase: NA
-
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
NCT00970333 ·Status: COMPLETED ·Phase: PHASE1
-
PPMI Tau PET Imaging
NCT04906590 ·Status: COMPLETED ·Phase: PHASE2
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
NCT07348276 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Application of 18F-FDOPA PET in Research of the Association Between HCV Infection and Parkinson's Disease.
NCT04618679 ·Status: UNKNOWN
-
18F-DPA-714 PET/MR in Dysfunctional Brain Diseases
NCT06851143 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Functional Neuroimaging in Parkinson's Disease
NCT04904068 ·Status: COMPLETED
-
Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease
NCT03288909 ·Status: UNKNOWN
-
Isotopic Imaging for Prodromal Alzheimer's Disease
NCT01231295 ·Status: COMPLETED
-
[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.
NCT02061722 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Vascular Abnormalities in Idiopathic Parkinson's Disease
NCT02045420 ·Status: UNKNOWN